Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: an in vitro model for treatment.
Identifieur interne : 002794 ( PubMed/Checkpoint ); précédent : 002793; suivant : 002795Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: an in vitro model for treatment.
Auteurs : J. Lisziewicz [États-Unis] ; D. Sun ; M. Klotman ; S. Agrawal ; P. Zamecnik ; R. GalloSource :
- Proceedings of the National Academy of Sciences of the United States of America [ 0027-8424 ] ; 1992.
Descripteurs français
- KwdFr :
- Cellules cultivées, Données de séquences moléculaires, Facteurs temps, Humains, Mutation, Oligonucléotides antisens (), Oligonucléotides antisens (pharmacologie), Réplication virale (), Survie cellulaire (), Séquence nucléotidique, Techniques in vitro, VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (croissance et développement), VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (génétique).
- MESH :
- croissance et développement : VIH-1 (Virus de l'Immunodéficience Humaine de type 1).
- génétique : VIH-1 (Virus de l'Immunodéficience Humaine de type 1).
- pharmacologie : Oligonucléotides antisens.
- Cellules cultivées, Données de séquences moléculaires, Facteurs temps, Humains, Mutation, Oligonucléotides antisens, Réplication virale, Survie cellulaire, Séquence nucléotidique, Techniques in vitro.
English descriptors
- KwdEn :
- Base Sequence, Cell Survival (drug effects), Cells, Cultured, HIV-1 (genetics), HIV-1 (growth & development), Humans, In Vitro Techniques, Molecular Sequence Data, Mutation, Oligonucleotides, Antisense (chemistry), Oligonucleotides, Antisense (pharmacology), Time Factors, Virus Replication (drug effects).
- MESH :
- chemical , chemistry : Oligonucleotides, Antisense.
- drug effects : Cell Survival, Virus Replication.
- genetics : HIV-1.
- growth & development : HIV-1.
- chemical , pharmacology : Oligonucleotides, Antisense.
- Base Sequence, Cells, Cultured, Humans, In Vitro Techniques, Molecular Sequence Data, Mutation, Time Factors.
Abstract
We have developed a culture system, simulating in vivo conditions of human immunodeficiency virus type 1 (HIV-1) infection, to evaluate the long-term efficacy of antisense oligonucleotide treatment. Five oligonucleotide phosphorothioates (28-mers), complementary to different regions of HIV-1 RNA, blocked replication of the virus in a sequence-specific manner at 1 microM concentration. Variations in antiviral activity were seen among the different oligonucleotides, revealing an effect of target selection. Mismatched or random oligonucleotide phosphorothioates delayed, but did not completely inhibit, HIV-1 replication. In the case of inhibition by a splice-acceptor-site antisense oligodeoxynucleotide, a break-through phenomenon occurred after 25 days of treatment, suggesting the development of an "escape mutant." This result did not occur when the inhibitory oligodeoxynucleotides were complementary to the primary-sequence areas of the rev-responsive element and rev-1 genes. Sequential treatment of HIV-1-infected cells with a combination of different antisense oligonucleotides, each administered once, also prevented the development of escape mutants. Our results suggest that chemotherapy based on specifically targeted antisense-oligonucleotide phosphorothioates may be an effective method for reducing the viral burden in HIV-1-infected individuals at clinically achievable oligonucleotide concentrations.
DOI: 10.1073/pnas.89.23.11209
PubMed: 1454800
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:1454800Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: an in vitro model for treatment.</title><author><name sortKey="Lisziewicz, J" sort="Lisziewicz, J" uniqKey="Lisziewicz J" first="J" last="Lisziewicz">J. Lisziewicz</name><affiliation wicri:level="2"><nlm:affiliation>Laboratory of Tumor Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Laboratory of Tumor Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda</wicri:cityArea></affiliation></author><author><name sortKey="Sun, D" sort="Sun, D" uniqKey="Sun D" first="D" last="Sun">D. Sun</name></author><author><name sortKey="Klotman, M" sort="Klotman, M" uniqKey="Klotman M" first="M" last="Klotman">M. Klotman</name></author><author><name sortKey="Agrawal, S" sort="Agrawal, S" uniqKey="Agrawal S" first="S" last="Agrawal">S. Agrawal</name></author><author><name sortKey="Zamecnik, P" sort="Zamecnik, P" uniqKey="Zamecnik P" first="P" last="Zamecnik">P. Zamecnik</name></author><author><name sortKey="Gallo, R" sort="Gallo, R" uniqKey="Gallo R" first="R" last="Gallo">R. Gallo</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1992">1992</date><idno type="RBID">pubmed:1454800</idno><idno type="pmid">1454800</idno><idno type="doi">10.1073/pnas.89.23.11209</idno><idno type="wicri:Area/PubMed/Corpus">002936</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002936</idno><idno type="wicri:Area/PubMed/Curation">002936</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002936</idno><idno type="wicri:Area/PubMed/Checkpoint">002794</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002794</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: an in vitro model for treatment.</title><author><name sortKey="Lisziewicz, J" sort="Lisziewicz, J" uniqKey="Lisziewicz J" first="J" last="Lisziewicz">J. Lisziewicz</name><affiliation wicri:level="2"><nlm:affiliation>Laboratory of Tumor Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Laboratory of Tumor Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda</wicri:cityArea></affiliation></author><author><name sortKey="Sun, D" sort="Sun, D" uniqKey="Sun D" first="D" last="Sun">D. Sun</name></author><author><name sortKey="Klotman, M" sort="Klotman, M" uniqKey="Klotman M" first="M" last="Klotman">M. Klotman</name></author><author><name sortKey="Agrawal, S" sort="Agrawal, S" uniqKey="Agrawal S" first="S" last="Agrawal">S. Agrawal</name></author><author><name sortKey="Zamecnik, P" sort="Zamecnik, P" uniqKey="Zamecnik P" first="P" last="Zamecnik">P. Zamecnik</name></author><author><name sortKey="Gallo, R" sort="Gallo, R" uniqKey="Gallo R" first="R" last="Gallo">R. Gallo</name></author></analytic><series><title level="j">Proceedings of the National Academy of Sciences of the United States of America</title><idno type="ISSN">0027-8424</idno><imprint><date when="1992" type="published">1992</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Base Sequence</term><term>Cell Survival (drug effects)</term><term>Cells, Cultured</term><term>HIV-1 (genetics)</term><term>HIV-1 (growth & development)</term><term>Humans</term><term>In Vitro Techniques</term><term>Molecular Sequence Data</term><term>Mutation</term><term>Oligonucleotides, Antisense (chemistry)</term><term>Oligonucleotides, Antisense (pharmacology)</term><term>Time Factors</term><term>Virus Replication (drug effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Cellules cultivées</term><term>Données de séquences moléculaires</term><term>Facteurs temps</term><term>Humains</term><term>Mutation</term><term>Oligonucléotides antisens ()</term><term>Oligonucléotides antisens (pharmacologie)</term><term>Réplication virale ()</term><term>Survie cellulaire ()</term><term>Séquence nucléotidique</term><term>Techniques in vitro</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (croissance et développement)</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (génétique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Oligonucleotides, Antisense</term></keywords><keywords scheme="MESH" qualifier="croissance et développement" xml:lang="fr"><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Cell Survival</term><term>Virus Replication</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>HIV-1</term></keywords><keywords scheme="MESH" qualifier="growth & development" xml:lang="en"><term>HIV-1</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Oligonucléotides antisens</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Oligonucleotides, Antisense</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Base Sequence</term><term>Cells, Cultured</term><term>Humans</term><term>In Vitro Techniques</term><term>Molecular Sequence Data</term><term>Mutation</term><term>Time Factors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Cellules cultivées</term><term>Données de séquences moléculaires</term><term>Facteurs temps</term><term>Humains</term><term>Mutation</term><term>Oligonucléotides antisens</term><term>Réplication virale</term><term>Survie cellulaire</term><term>Séquence nucléotidique</term><term>Techniques in vitro</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We have developed a culture system, simulating in vivo conditions of human immunodeficiency virus type 1 (HIV-1) infection, to evaluate the long-term efficacy of antisense oligonucleotide treatment. Five oligonucleotide phosphorothioates (28-mers), complementary to different regions of HIV-1 RNA, blocked replication of the virus in a sequence-specific manner at 1 microM concentration. Variations in antiviral activity were seen among the different oligonucleotides, revealing an effect of target selection. Mismatched or random oligonucleotide phosphorothioates delayed, but did not completely inhibit, HIV-1 replication. In the case of inhibition by a splice-acceptor-site antisense oligodeoxynucleotide, a break-through phenomenon occurred after 25 days of treatment, suggesting the development of an "escape mutant." This result did not occur when the inhibitory oligodeoxynucleotides were complementary to the primary-sequence areas of the rev-responsive element and rev-1 genes. Sequential treatment of HIV-1-infected cells with a combination of different antisense oligonucleotides, each administered once, also prevented the development of escape mutants. Our results suggest that chemotherapy based on specifically targeted antisense-oligonucleotide phosphorothioates may be an effective method for reducing the viral burden in HIV-1-infected individuals at clinically achievable oligonucleotide concentrations.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1454800</PMID><DateCompleted><Year>1993</Year><Month>01</Month><Day>07</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>89</Volume><Issue>23</Issue><PubDate><Year>1992</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc. Natl. Acad. Sci. U.S.A.</ISOAbbreviation></Journal><ArticleTitle>Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: an in vitro model for treatment.</ArticleTitle><Pagination><MedlinePgn>11209-13</MedlinePgn></Pagination><Abstract><AbstractText>We have developed a culture system, simulating in vivo conditions of human immunodeficiency virus type 1 (HIV-1) infection, to evaluate the long-term efficacy of antisense oligonucleotide treatment. Five oligonucleotide phosphorothioates (28-mers), complementary to different regions of HIV-1 RNA, blocked replication of the virus in a sequence-specific manner at 1 microM concentration. Variations in antiviral activity were seen among the different oligonucleotides, revealing an effect of target selection. Mismatched or random oligonucleotide phosphorothioates delayed, but did not completely inhibit, HIV-1 replication. In the case of inhibition by a splice-acceptor-site antisense oligodeoxynucleotide, a break-through phenomenon occurred after 25 days of treatment, suggesting the development of an "escape mutant." This result did not occur when the inhibitory oligodeoxynucleotides were complementary to the primary-sequence areas of the rev-responsive element and rev-1 genes. Sequential treatment of HIV-1-infected cells with a combination of different antisense oligonucleotides, each administered once, also prevented the development of escape mutants. Our results suggest that chemotherapy based on specifically targeted antisense-oligonucleotide phosphorothioates may be an effective method for reducing the viral burden in HIV-1-infected individuals at clinically achievable oligonucleotide concentrations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lisziewicz</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratory of Tumor Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Klotman</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Agrawal</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Zamecnik</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Gallo</LastName><ForeName>R</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>A1-24846</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30-12708-17</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016376">Oligonucleotides, Antisense</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CitationSubset>X</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015497" MajorTopicYN="N">HIV-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000254" MajorTopicYN="N">growth & development</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016376" MajorTopicYN="N">Oligonucleotides, Antisense</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1992</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1992</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1992</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1454800</ArticleId><ArticleId IdType="pmc">PMC50519</ArticleId><ArticleId IdType="doi">10.1073/pnas.89.23.11209</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cell. 1990 Nov 2;63(3):601-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2225067</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1990 Jun;87(12):4571-5</Citation><ArticleIdList><ArticleId IdType="pubmed">2191294</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 1990 Feb 23;60(4):675-83</Citation><ArticleIdList><ArticleId IdType="pubmed">2406030</ArticleId></ArticleIdList></Reference><Reference><Citation>J Natl Cancer Inst. 1987 Apr;78(4):663-6</Citation><ArticleIdList><ArticleId IdType="pubmed">2435942</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1989 Jun;86(11):4244-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2471199</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1985 Jan 24-30;313(6000):277-84</Citation><ArticleIdList><ArticleId IdType="pubmed">2578615</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1989 Oct;86(20):7790-4</Citation><ArticleIdList><ArticleId IdType="pubmed">2682627</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1985 Jul 5;229(4708):69-73</Citation><ArticleIdList><ArticleId IdType="pubmed">2990040</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1986 Jun;83(12):4143-6</Citation><ArticleIdList><ArticleId IdType="pubmed">3012555</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1988 Aug;85(15):5507-11</Citation><ArticleIdList><ArticleId IdType="pubmed">3041414</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1988 Oct;85(19):7079-83</Citation><ArticleIdList><ArticleId IdType="pubmed">3174622</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1988 Oct;85(20):7448-51</Citation><ArticleIdList><ArticleId IdType="pubmed">3174646</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biochem Biophys Methods. 1986 Sep;13(2):97-102</Citation><ArticleIdList><ArticleId IdType="pubmed">3772027</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1984 May 4;224(4648):497-500</Citation><ArticleIdList><ArticleId IdType="pubmed">6200935</ArticleId></ArticleIdList></Reference><Reference><Citation>Gene. 1988 Dec 10;72(1-2):343-7</Citation><ArticleIdList><ArticleId IdType="pubmed">3243433</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Biotechnol. 1992 May;10(5):152-8</Citation><ArticleIdList><ArticleId IdType="pubmed">1368317</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1992 Jan;66(1):600-7</Citation><ArticleIdList><ArticleId IdType="pubmed">1727504</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1992 Jan 15;89(2):758-62</Citation><ArticleIdList><ArticleId IdType="pubmed">1731351</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 1991 Apr 19;65(2):241-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2015625</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucleic Acids Res. 1991 Jun 25;19(12):3359-68</Citation><ArticleIdList><ArticleId IdType="pubmed">2062653</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1990 Nov 25;265(33):20172-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2173699</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 1990 Jun 29;61(7):1271-6</Citation><ArticleIdList><ArticleId IdType="pubmed">2364429</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Maryland</li></region></list><tree><noCountry><name sortKey="Agrawal, S" sort="Agrawal, S" uniqKey="Agrawal S" first="S" last="Agrawal">S. Agrawal</name><name sortKey="Gallo, R" sort="Gallo, R" uniqKey="Gallo R" first="R" last="Gallo">R. Gallo</name><name sortKey="Klotman, M" sort="Klotman, M" uniqKey="Klotman M" first="M" last="Klotman">M. Klotman</name><name sortKey="Sun, D" sort="Sun, D" uniqKey="Sun D" first="D" last="Sun">D. Sun</name><name sortKey="Zamecnik, P" sort="Zamecnik, P" uniqKey="Zamecnik P" first="P" last="Zamecnik">P. Zamecnik</name></noCountry><country name="États-Unis"><region name="Maryland"><name sortKey="Lisziewicz, J" sort="Lisziewicz, J" uniqKey="Lisziewicz J" first="J" last="Lisziewicz">J. Lisziewicz</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002794 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002794 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:1454800
|texte= Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: an in vitro model for treatment.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:1454800" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |